Compare Axon Enterprise Inc (AXON) vs Viatris Inc (VTRS) Price & Performance

AXON trades at $599.78, up 0.58% on the day, consolidating after a strong uptrend. The stock shows bullish technical signals with support near $616 and resistance at $649. Fundamentally, Q2 2026 revenue grew 35% year-over-year to $904 million, marking the tenth consecutive quarter of growth above 30%, with a net income margin of 6.19%. Analyst consensus is strongly bullish with an $685 price target, though valuation multiples remain elevated.

The outlook is positive given robust revenue growth and AI-driven expansion, but the high P/E of 265 presents a significant risk. Investors face a trade-off between strong operational execution and demanding valuations. Near-term catalysts include Q3 2026 earnings and continued execution on the $15.1B future contracted bookings pipeline.

Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.

Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.